AstraZeneca announced positive late-stage trial results for a two-drug combination treating a resistant form of lung cancer. The combo pairs Tagrisso, an established lung cancer pill, with Orpathys, a newer drug targeting the MET protein that causes resistance. Patients on both drugs lived longer and delayed disease progression compared to standard chemotherapy. The all-oral treatment, already approved in China, may soon gain global approval, providing a new option for patients facing limited treatments.
Jefferies estimates a 59% probability that AstraZeneca's kidney drug zibotentan will succeed in the phase 3 ZENITH-HP trial, with results expected in the first half of 2027. The trial tests zibotentan combined with Farxiga in patients with high prote...
Oracle and AstraZeneca have entered a collaboration to combine AstraZeneca's scientific expertise with Oracle's AI, cloud, and real-world data capabilities. The partnership aims to accelerate clinical trials by helping clinicians identify eligible pa...
